Cytokinetics gets bump after DMC says CVOT should proceed

Cytokinetics added $1.63 (19%) to $10.19 on Wednesday after it said a DMC recommended the Phase III GALACTIC-HF cardiovascular outcomes trial

Read the full 210 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE